Sales are quantitatively trivial and structurally typical of post-vesting tax-related liquidation. Flush with institutional bullishness (95% analyst buy rating) and a ~$3.7B market cap, this insider activity provides no credible trading signal. No action warranted; monitor any future large-scale C-suite selling or 10b5-1 establishment.
ORKA drugs
ORKA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 19 $57.50entry
- T+1 · 6mo ago +5.51%α +4.47% · $60.67
- T+5 · 6mo ago +0.85%α −1.44% · $57.99
- T+20 · 5mo ago +23.27%α +22.28% · $70.88
- T+60 · 3mo ago +88.03%α +81.74% · $108.12
Price Chart
How similar events traded
Executive Summary
Two senior insiders at Oruka Therapeutics (CMO & SVP Finance) collectively sold ~$540K of stock on May 15-18, 2026, following derivative exercises. This represents only ~0.015% of the $3.7B market cap, a trivial dollar value relative to company size. Cluster insider SALES are not amplified by cross-filing context but the absolute materiality is negligible, making this a routine liquidity/vesting event rather than an informed signal.
Key Financial Metrics
Key Facts
- CMO Joana Goncalves sold 4,800 shares at $61.56 for $295K on May 15
- SVP Finance Arjun Agarwal sold 4,190 shares at $58.34 for $244K on May 18
- Both sales followed derivative exercises (options/RSAs), indicative of tax-covering liquidity sales
- Total cluster value $540K = ~0.015% of $3.7B market cap
- No C-suite CEO/CFO participation; both are second-tier executives one level below C-suite
Financial Impact
Cluster sale value of ~$540K represents 0.015% of market cap, well below 0.1% threshold for materiality
Risk Factors
- Potential further insider sales if share price continues to weaken from May highs
- No CEO or CFO participation could suggest management confidence remains intact
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ORKA-1779142117031 |
Track record
40 reports on ORKA
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 11 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers